Join
Live feed
·
PRReleasevia Quantisnow
AnaptysBio Inc. logo

Anaptys Announces Phase 2b Trial of ANB032, a BTLA Agonist, Did Not Meet Primary or Secondary Endpoints in Atopic Dermatitis

ByQuantisnow·Wall Street's wire, on your screen.
ANAB· AnaptysBio Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track ANAB (AnaptysBio Inc.) and more on Quantisnow.